Compare BridgeBio Pharma Inc (BBIO) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Quantumscape Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Quantumscape Corp trades at $6.33 (market cap $3.81B). The key difference: BridgeBio Pharma Inc is far larger — about 4.4× Quantumscape Corp's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | QS | |
|---|---|---|
Market Cap | $16.61B | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $18.44 |
52-Week Low | $47.29 | $4.89 |
Enterprise Value | $18.16B | $3.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
QuantumScape (QS) trades at $6.075, up 9.86% in the last session, with a bullish technical signal overall despite mixed moving averages and oscillators. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, and has no revenue as it develops solid-state battery technology. Recent news highlights partnerships with Volkswagen and Honda, but the stock fell 31% in July 2026 amid commercialization delays.
The outlook remains speculative, with potential upside tied to successful battery commercialization by 2029, but high execution risks and persistent losses warrant caution. Analyst sentiment is neutral to bearish, with 73% hold ratings, reflecting uncertainty over timelines and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
